logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hiromu Kondo

University of Shizuoka
H指数:24
被引数:1,860

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis

不可切除肝细胞癌患者接受阿替利珠单抗联合贝伐珠单抗治疗时的初始治疗反应有助于治疗期间肝功能的变化：一项多中心分析

Oncology
IF1.8
2026-01-010
PRE
Suzuki, Takanori; Sato, Ryo; Matsuura, Kentaro; Kato, Daisuke; Hayashi, Katsumi; Okayama, Kohei; Okumura, Fumihiro; Sobue, Satoshi; Kusakabe, Atsunori; Hasegawa, Izumi; Narita, Kiyoto; Mizoshita, Tsutomu; Kimura, Yoshihide; Kondo, Hiromu; Kojima, Hisayo; Hayashi, Kazuki; Ozasa, Atsushi; Kawamura, Hayato; Fujiwara, Kei; Nojiri, Shunsuke; Kataoka, Hiromi
The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis
HEPATOLOGY RESEARCH
IF3.4
2025-12-010
PRE
Sato, Ryo; Suzuki, Takanori; Matsuura, Kentaro; Kato, Daisuke; Hayashi, Katsumi; Okayama, Kohei; Okumura, Fumihiro; Sobue, Satoshi; Kusakabe, Atsunori; Hasegawa, Izumi; Narita, Kiyoto; Mizoshita, Tsutomu; Kimura, Yoshihide; Kondo, Hiromu; Kojima, Hisayo; Hayashi, Kazuki; Ozasa, Atsushi; Kawamura, Hayato; Fujiwara, Kei; Nojiri, Shunsuke; Kataoka, Hiromi
Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis

durvalumab联合tremelimumab治疗第二疗程开始时的中性粒细胞与淋巴细胞比率预测晚期肝细胞癌患者的治疗效果: 一项多中心分析

HEPATOLOGY RESEARCH
IF3.4
2025-03-010
PRE
Suzuki, Takanori; Matsuura, Kentaro; Sobue, Satoshi; Kato, Daisuke; Hayashi, Katsumi; Kondo, Hiromu; Anbe, Kaiki; Mizoshita, Tsutomu; Okayama, Kohei; Okumura, Fumihiro; Kimura, Yoshihide; Ozasa, Atsushi; Inada, Hiroki; Tokunaga, Takayuki; Narahara, Satoshi; Kawamura, Hayato; Fujiwara, Kei; Nojiri, Shunsuke; Kataoka, Hiromi; Tanaka, Yasuhito
The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
HEPATOLOGY RESEARCH
IF3.4
2023-02-1812
PRE
Matoya, Sho; Suzuki, Takanori; Matsuura, Kentaro; Suzuki, Yuta; Okumura, Fumihiro; Nagura, Yoshihito; Sobue, Satoshi; Kuroyanagi, Keita; Kusakabe, Atsunori; Koguchi, Hiroki; Hasegawa, Izumi; Miyaki, Tomokatsu; Tanaka, Yoshito; Kondo, Hiromu; Kimura, Yoshihide; Ozasa, Atsushi; Kawamura, Hayato; Kuno, Kayoko; Fujiwara, Kei; Nojiri, Shunsuke; Kataoka, Hiromi

研究方向

暂未获取到该数据
I
Itaru Naitoh
H 指数:31论文数:238被引数:3,468
K
Kazuki Hayashi
H 指数:31论文数:271被引数:3,542
M
Michihiro Yoshida
H 指数:23论文数:165被引数:2,160
T
Takashi Joh
H 指数:66论文数:1,004被引数:1.6万
K
Katsuyuki Miyabe
H 指数:25论文数:145被引数:2,683
Y
Yasuki Hori
H 指数:20论文数:173被引数:1,233
T
Takahiro Nakazawa
H 指数:50论文数:289被引数:9,554
S
Shuya Shimizu
H 指数:18论文数:67被引数:890
F
Fumihiro Okumura
H 指数:24论文数:145被引数:2,089
S
Shuichiro Umemura
H 指数:16论文数:56被引数:684